Stock listing
NASDAQ:XBIT XBiotech Inc. Stock
Home listing (NASDAQ) of XBiotech Inc.
Follow XBiotech Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:XBIT
$1.73 USD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $1.61 – $1.81 USDNov 20, 2026
- Volume
- 140,203 sharesNov 20, 2026
- Market cap
- $52.74M USDAt the close on Nov 20, 2026 · price × 30.49M shares outstanding
- 52-week range
- $1.61 – $2.73 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $130,233 USDMedian day 41,957 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:XBIT · Home | $1.73 USD | 0.00 (0.0%) | 140,203 | $1.68 | $1.81 | $1.61 | $1.73 | Close on Nov 20, 2026 |
| Frankfurt:4XB | €1.546 EUR | +0.066 (+4.5%) | — | €1.38 | €1.546 | €1.38 | €1.48 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:XBIT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.73 | 0.00 | 0.0% | $1.68 | $1.81 | $1.61 | 140,203 | |
| $1.73 | -0.05 | -2.8% | $1.77 | $1.789 | $1.71 | 60,735 | |
| $1.78 | -0.07 | -3.8% | $1.86 | $1.87 | $1.78 | 62,583 | |
| $1.85 | -0.11 | -5.6% | $1.97 | $1.97 | $1.81 | 111,272 | |
| $1.96 | 0.00 | 0.0% | $1.95 | $1.99 | $1.95 | 105,424 | |
| $1.96 | +0.01 | +0.5% | $1.96 | $1.99 | $1.95 | 16,242 | |
| $1.95 | -0.02 | -1.0% | $1.945 | $1.982 | $1.945 | 18,552 | |
| $1.97 | +0.06 | +3.1% | $1.91 | $1.98 | $1.91 | 57,456 | |
| $1.91 | +0.02 | +1.1% | $1.89 | $1.92 | $1.86 | 14,540 | |
| $1.89 | +0.02 | +1.1% | $1.88 | $1.946 | $1.86 | 25,248 | |
| $1.87 | -0.08 | -4.1% | $1.95 | $2.005 | $1.852 | 31,644 | |
| $1.95 | -0.04 | -2.0% | $2.01 | $2.01 | $1.92 | 94,251 | |
| $1.99 | +0.07 | +3.6% | $1.90 | $2.13 | $1.90 | 132,747 | |
| $1.92 | +0.04 | +2.1% | $1.98 | $1.99 | $1.865 | 61,436 | |
| $1.88 | -0.06 | -3.1% | $1.93 | $1.982 | $1.865 | 50,560 | |
| $1.94 | -0.05 | -2.5% | $1.98 | $1.98 | $1.87 | 73,978 | |
| $1.99 | +0.14 | +7.6% | $1.86 | $2.04 | $1.80 | 309,975 | |
| $1.85 | 0.00 | 0.0% | $1.85 | $1.952 | $1.81 | 69,105 | |
| $1.85 | -0.08 | -4.1% | $1.92 | $1.927 | $1.82 | 136,289 | |
| $1.93 | -0.04 | -2.0% | $1.95 | $1.95 | $1.86 | 121,736 | |
| $1.97 | -0.02 | -1.0% | $1.98 | $1.98 | $1.94 | 7,668 | |
| $1.99 | -0.03 | -1.5% | $2.04 | $2.04 | $1.98 | 58,251 | |
| $2.02 | +0.02 | +1.0% | $2.03 | $2.08 | $1.99 | 41,228 | |
| $2.00 | -0.12 | -5.7% | $2.13 | $2.13 | $1.905 | 384,627 | |
| $2.12 | -0.04 | -1.9% | $2.16 | $2.22 | $2.10 | 68,271 | |
| $2.16 | 0.00 | 0.0% | $2.16 | $2.26 | $2.13 | 85,022 | |
| $2.16 | 0.00 | 0.0% | $2.16 | $2.235 | $2.15 | 66,074 | |
| $2.16 | -0.13 | -5.7% | $2.27 | $2.29 | $2.15 | 78,446 | |
| $2.29 | 0.00 | 0.0% | $2.29 | $2.33 | $2.25 | 41,957 | |
| $2.29 | +0.09 | +4.1% | $2.21 | $2.29 | $2.195 | 88,032 | |
| $2.20 | +0.01 | +0.5% | $2.19 | $2.22 | $2.15 | 13,021 | |
| $2.19 | +0.03 | +1.4% | $2.16 | $2.23 | $2.16 | 100,377 | |
| $2.16 | -0.02 | -0.9% | $2.18 | $2.19 | $2.16 | 11,714 | |
| $2.18 | -0.01 | -0.5% | $2.20 | $2.20 | $2.18 | 32,740 | |
| $2.19 | -0.01 | -0.5% | $2.20 | $2.20 | $2.19 | 25,236 | |
| $2.20 | +0.01 | +0.5% | $2.19 | $2.20 | $2.19 | 13,563 | |
| $2.19 | +0.01 | +0.5% | $2.18 | $2.21 | $2.18 | 62,849 | |
| $2.18 | +0.03 | +1.4% | $2.13 | $2.18 | $2.13 | 9,549 | |
| $2.15 | -0.02 | -0.9% | $2.16 | $2.19 | $2.15 | 41,689 | |
| $2.17 | +0.01 | +0.5% | $2.156 | $2.17 | $2.15 | 10,829 | |
| $2.16 | -0.02 | -0.9% | $2.17 | $2.19 | $2.16 | 24,000 | |
| $2.18 | 0.00 | 0.0% | $2.19 | $2.20 | $2.17 | 40,037 | |
| $2.18 | 0.00 | 0.0% | $2.21 | $2.21 | $2.18 | 9,099 | |
| $2.18 | -0.01 | -0.5% | $2.19 | $2.20 | $2.17 | 31,839 | |
| $2.19 | +0.01 | +0.5% | $2.20 | $2.22 | $2.16 | 66,092 | |
| $2.18 | +0.03 | +1.4% | $2.17 | $2.18 | $2.14 | 32,119 | |
| $2.15 | -0.045 | -2.1% | $2.19 | $2.22 | $2.15 | 49,067 | |
| $2.195 | +0.025 | +1.2% | $2.17 | $2.20 | $2.16 | 18,231 | |
| $2.17 | -0.02 | -0.9% | $2.20 | $2.20 | $2.17 | 21,882 | |
| $2.19 | +0.02 | +0.9% | $2.19 | $2.21 | $2.18 | 31,325 | |
| $2.17 | -0.01 | -0.5% | $2.17 | $2.18 | $2.15 | 20,270 | |
| $2.18 | 0.00 | 0.0% | $2.19 | $2.27 | $2.15 | 23,958 | |
| $2.18 | -0.02 | -0.9% | $2.20 | $2.21 | $2.18 | 45,362 | |
| $2.20 | 0.00 | 0.0% | $2.20 | $2.25 | $2.19 | 118,606 | |
| $2.20 | +0.01 | +0.5% | $2.20 | $2.22 | $2.19 | 136,189 | |
| $2.19 | -0.03 | -1.4% | $2.22 | $2.22 | $2.19 | 109,028 | |
| $2.22 | -0.08 | -3.5% | $2.29 | $2.309 | $2.19 | 221,171 | |
| $2.30 | +0.03 | +1.3% | $2.26 | $2.31 | $2.25 | 23,051 | |
| $2.27 | -0.03 | -1.3% | $2.32 | $2.32 | $2.26 | 7,073 | |
| $2.30 | -0.01 | -0.4% | $2.28 | $2.33 | $2.26 | 32,783 | |
| $2.31 | +0.01 | +0.4% | $2.30 | $2.32 | $2.29 | 21,900 | |
| $2.30 | -0.01 | -0.4% | $2.30 | $2.32 | $2.23 | 52,245 | |
| $2.31 | +0.03 | +1.3% | $2.28 | $2.32 | $2.26 | 27,778 | |
| $2.28 | -0.03 | -1.3% | $2.26 | $2.32 | $2.26 | 11,043 | |
| $2.31 | 0.00 | 0.0% | $2.30 | $2.33 | $2.26 | 10,039 |
- Ticker
- NASDAQ:XBIT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 23, 2026
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
Latest news
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
Oct 23, 2026
Closed $1.93 (-2.0%) on Oct 23, 2026
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
Oct 19, 2026
Closed $2.00 (-5.7%) on Oct 19, 2026
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
Jun 15, 2026
Closed $2.35 (+0.4%) on Jun 15, 2026
XBiotech Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 3 in the last 12 months · 49 in all · newest Oct 23, 2026 · oldest 2019
- Decks
- 2 decks · latest Apr 21, 2017
Where XBiotech Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:XBIT · Home listing · This page | NASDAQ | United States | USD |
| Lang & Schwarz:A14QF1 | Lang & Schwarz | Germany | EUR |
| gettex:4XB | gettex | Germany | EUR |
| LS Exchange:A14QF1 | LS Exchange | Germany | EUR |
| BOATS:XBIT | BOATS | United States | USD |
| BX Swiss:4XB | BX Swiss | Switzerland | CHF |
| Frankfurt:4XB | Frankfurt | Germany | EUR |
| Tradegate:4XB | Tradegate | Germany | EUR |
| Dusseldorf:4XB | Dusseldorf | Germany | EUR |
| Munich:4XB | Munich | Germany | EUR |
| Stuttgart:4XB | Stuttgart | Germany | EUR |
Valuation
Price/book 0.4× against a median of 0.9×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$52.29M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.52
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| XBiotech Inc. · NASDAQ:XBIT | US$52.74M | −US$52.29M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 0.52 |
| Island Pharmaceuticals Ltd · ASX:ILA | US$54.84M | US$46.32M | n/a | 248× | n/a | 6.2× | n/a | 0.0× | n/a |
| Anavex Life Sciences Corp. · NASDAQ:AVXL | US$54.83M | −US$63.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 2.39 |
| Nordicus Partners Corp · OTC:NORD | US$54.44M | US$54.44M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.45 |
| Boundless Bio, Inc. · NASDAQ:BOLD | US$53.61M | −US$9.28M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.65 |
| Xilio Therapeutics, Inc. · NASDAQ:XLO | US$53.40M | −US$62.82M | n/a | −1.1× | n/a | 0.8× | −20.9% | 0.1× | 0.76 |
| Impact BioMedical, Inc. · AMEX:IBO | US$53.31M | US$53.29M | 33.0× | 1,402× | n/a | 5.3× | n/a | 0.0× | 0.06 |
| Bonus Biogroup Ltd. · TASE:BONS | US$52.22M | US$54.52M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| iBio, Inc. · NASDAQ:IBIO | US$51.45M | −US$23.13M | n/a | −21.5× | n/a | 0.7× | n/a | 0.0× | 2.01 |
| Sirnaomics Ltd. · HKEX:2257 | US$51.13M | US$69.20M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cinclus Pharma Holding AB · OMXSTO:CINPHA | US$51.07M | US$13.13M | n/a | 3.8× | n/a | 2.6× | −765.8% | 0.0× | n/a |
| Median of the others | US$53.36M | US$29.73M | 33.0× | 3.8× | 0.9× | −393.3% | 0.0× | 0.71 |
Team and board
Officers
| Officer | Role |
|---|---|
| Sushma Shivaswamy | Chief Scientific Officer, Interim Chief Executive Officer |
| Mike Cavalier | Vice President of Manufacturing |
| Norma Gonzalez | Vice President of Quality |
| Qian Wu | Senior Vice President of Clinical Operations and Analytical Quality |
| John Simard | Founder, Chairman of the Board, Scientific Advisor |
Board
| Director | Role |
|---|---|
| John Simard | Founder, Chairman of the Board, Scientific Advisor |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 | +0.5% |
| Q2 2026 | Aug 13, 2026 | −6.5% |
| Q4 2025 | Feb 25, 2026 | +0.4% |
| Q3 2025 | Nov 28, 2025 | +5.7% |
| Q2 2025 | Aug 29, 2025 | −10.9% |
| Q1 2025 | May 8, 2025 · Before open | +2.1% |
| Q4 2024 | Mar 13, 2025 · Before open | −4.6% |
| Q3 2024 | Nov 7, 2024 · Before open | −10.8% |
| Q2 2024 | Aug 12, 2024 · Before open | −0.8% |
| Q1 2024 | May 10, 2024 · Before open | −3.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 15, 2024 · Before open | −7.1% |
| Q3 2023 | Nov 9, 2023 · Before open | −3.2% |
| Q2 2023 | Aug 11, 2023 · Before open | +0.2% |
| Q1 2023 | May 10, 2023 · After close | +2.1% |
| Q4 2022 | Mar 15, 2023 · After close | +1.2% |
| Q3 2022 | Nov 9, 2022 · Before open | −0.8% |
| Q2 2022 | Aug 9, 2022 · After close | +0.8% |
| Q1 2022 | May 11, 2022 | −6.6% |
| Q4 2021 | Mar 2, 2022 | +0.5% |
| Quarter to Sep 30, 2021 | Nov 11, 2021 | −3.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (April 2017) | Technical | 37 slides | Apr 21, 2017 |
| Investor Presentation (December 2016) | Investor deck | 31 slides | Dec 6, 2016 |
IPO
Priced at US$19.00 a share on Apr 14, 2015.
- Price
- US$19.00 a share
- Shares offered
- 4,000,000 shares of common stock
- Offering size
- US$76 million
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 10, 2014 |
| Filed publicly | Feb 2, 2015 |
| Amended 3 times | Newest Apr 10, 2015 |
| Shares registered with an exchange | Apr 14, 2015 |
| Declared effective by the SEC | Apr 14, 2015 |
| Final prospectus, with the price | Apr 16, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 16, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Apr 14, 2015 |
| EFFECT · Notice that a registration is effective | Apr 14, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 14, 2015 |
| CORRESP · Letter to the SEC | Apr 10, 2015 |
| CORRESP · Letter to the SEC | Apr 10, 2015 |
| S-1/A · Registration statement, amended | Apr 10, 2015 |
| CORRESP · Letter to the SEC | Apr 9, 2015 |
| UPLOAD · Letter from the SEC | Apr 7, 2015 |
| FWP · Free writing prospectus | Mar 27, 2015 |
All 22 filings
| Filing | Filed |
|---|---|
| FWP · Free writing prospectus | Mar 27, 2015 |
| CORRESP · Letter to the SEC | Mar 27, 2015 |
| S-1/A · Registration statement, amended | Mar 27, 2015 |
| UPLOAD · Letter from the SEC | Mar 24, 2015 |
| CORRESP · Letter to the SEC | Mar 20, 2015 |
| CORRESP · Letter to the SEC | Mar 10, 2015 |
| S-1/A · Registration statement, amended | Mar 10, 2015 |
| UPLOAD · Letter from the SEC | Feb 12, 2015 |
| CORRESP · Letter to the SEC | Feb 2, 2015 |
| S-1 · Registration statement | Feb 2, 2015 |
| UPLOAD · Letter from the SEC | Jan 9, 2015 |
| DRS · Draft registration statement | Dec 10, 2014 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 16, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 4.01M | 18.4M | 44.0M | 0 | 0 | 0 | 0 |
| Cost of revenue | 1.69M | 1.75M | 0 | 651.0K | 5.82M | 34.5M | 0 | 0 | 1.48M | 698.0K |
| Gross profit | -1.69M | -1.75M | 0 | 3.36M | 12.6M | 9.45M | 0 | 0 | -1.48M | -698.0K |
| Research and development | 47.4M | 37.8M | 32.8M | 31.5M | 28.3M | 9.53M | 24.1M | 15.7M | 26.4M | 42.5M |
| Selling, general and administrative | 8.29M | 4.71M | 4.66M | 6.30M | 9.39M | 18.2M | 7.14M | 5.27M | 7.63M | 10.3M |
| Operating income | -55.7M | -42.5M | -37.5M | -34.5M | -25.1M | -18.3M | -31.2M | -21.0M | -34.1M | -52.8M |
| Depreciation and amortization | 1.69M | 1.75M | 1.70M | 2.61M | 2.65M | 2.24M | 2.36M | 2.43M | 1.48M | 698.0K |
| EBITDA | -54.0M | -40.7M | -35.8M | -31.9M | -22.4M | -16.0M | -28.9M | -18.6M | -32.6M | -52.1M |
| Interest expense | 88.0K | 807.0K | 0 | 902.0K | 1.09M | 8.95M | 748.8M | 0 | 0 | 0 |
| Income before tax | -45.3M | -38.6M | -24.3M | -33.6M | -25.5M | -12.8M | 718.5M | -21.1M | -33.1M | -52.8M |
| Income tax | 235.0K | -32.0K | 244.0K | -688.0K | -8.04M | -1.61M | 49.8M | 0 | 0 | 0 |
| Net income | -45.5M | -38.5M | -24.6M | -32.9M | -17.4M | -11.2M | 668.6M | -21.1M | -33.1M | -52.8M |
| Earnings per share, basic | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 | -0.36 | 17.17 | -0.59 | -0.95 | -1.63 |
| Earnings per share, diluted | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 | -0.36 | 14.44 | -0.59 | -0.95 | -1.63 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 125.6M | 172.7M | 200.0M | 157.3M | 237.0M | 237.4M | 714.6M | 15.8M | 31.8M | 34.3M |
| Short-term investments | 0 | 60.2M | 0 | 0 | 0 | |||||
| Receivables | 360.0K | 700.0K | 860.0K | 1.22M | 0 | 4.11M | 0 | |||
| Inventory | -8.95M | -6.57M | 0 | 0 | ||||||
| Current assets | 127.0M | 174.6M | 201.7M | 219.8M | 246.9M | 325.9M | 716.3M | 17.0M | 33.3M | 36.9M |
| Property, plant and equipment | 23.1M | 24.5M | 24.9M | 26.3M | 28.3M | 27.3M | 25.2M | 27.3M | 29.6M | 10.1M |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 150.1M | 199.1M | 226.6M | 246.1M | 275.2M | 353.7M | 816.9M | 44.3M | 63.0M | 67.0M |
| Accounts payable | 1.53M | 2.22M | 2.52M | 2.41M | 2.07M | 2.49M | 2.15M | 1.65M | 1.73M | 4.43M |
| Current liabilities | 7.93M | 15.1M | 6.10M | 4.07M | 3.45M | 3.98M | 60.2M | 2.94M | 2.79M | 7.96M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 10.3M | |||||||||
| Total liabilities | 9.73M | 16.8M | 7.77M | 5.70M | 5.79M | 5.11M | 61.2M | 2.95M | 2.81M | 7.99M |
| Shareholders' equity | 140.3M | 182.3M | 218.8M | 240.4M | 269.4M | 348.6M | 755.6M | 41.4M | 60.2M | 59.1M |
| Shares outstanding | 30.5M | 30.5M | 30.4M | 30.4M | 30.4M | 29.3M | 41.5M | 35.9M | 35.4M | 32.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -39.9M | -31.0M | -18.7M | -14.8M | 69.4M | -65.1M | -18.3M | -16.5M | -33.6M | -46.0M |
| Capital spending | -289.0K | -1.30M | -362.0K | -585.0K | -3.52M | -3.73M | -204.0K | -122.0K | -1.41M | -4.75M |
| Free cash flow | -40.2M | -32.3M | -19.1M | -15.4M | 65.9M | -68.9M | -18.5M | -16.7M | -35.1M | -50.8M |
| Cash from investing | -289.0K | -1.30M | 61.5M | -63.9M | -3.52M | -3.73M | 674.8M | -122.0K | -1.41M | -13.9M |
| Cash from financing | -10.3M | 10.4M | -9.00K | 0 | -67.0M | -409.7M | 42.1M | 201.0K | 33.3M | 2.94M |
| Dividends paid | 0 | -75.0M | 0 | 0 | -75.0M | 0 | 0 | |||
| Share buybacks | 0 | -14.0K | 0 | 8.00M | -420.0M | 41.8M | 201.0K | 33.3M | 2.94M | |
| Change in cash | -47.1M | -27.3M | 42.7M | -79.7M | -383.0K | -477.2M | 698.8M | -15.9M | -2.56M | -56.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 18, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 26, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Oct 2, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 2, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2026 | Annual report | SEC |
| 10-K · Annual report | Mar 13, 2026 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 23, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 23, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Dec 9, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Oct 15, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 3, 2025 | Material contract | SEC |
| 3 · Initial statement of ownership | Sep 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 2, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Jul 7, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 7, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 24, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2025 | Annual report | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| 8-K · Current report | Mar 31, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 18, 2025 | Annual report | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 27, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 27, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 31, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | May 1, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 1, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 1, 2024 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | May 1, 2024 | Annual report | SEC |
| 10-K/A · Annual report, amended | Apr 24, 2024 | Annual report | SEC |
| 10-K · Annual report | Mar 15, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 4, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2023 | Meeting outcome | SEC |
| SC TO-I/A | Jun 20, 2023 | Acquisition or disposal | SEC |
| SC TO-I | May 17, 2023 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | May 10, 2023 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Mar 15, 2023 | Annual report | SEC |
| 3 · Initial statement of ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2023 | Insider trade | SEC |
| 8-K · Current report | Feb 14, 2023 | Management or board change | SEC |
| SC 13G · Big-stake notice | Feb 10, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 10, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 10, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 12, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2022 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 9, 2022 | Quarterly report | SEC |
| 8-K · Current report | Jun 29, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 27, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2022 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jun 16, 2022 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | May 13, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 13, 2022 | Meeting notice | SEC |
| 8-K · Current report | May 13, 2022 | Current report | SEC |
| 10-Q · Quarterly report | May 10, 2022 | Quarterly report | SEC |
| 10-K · Annual report | Mar 15, 2022 | Annual report | SEC |
| SC 13G · Big-stake notice | Feb 15, 2022 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 15, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 15, 2022 | Insider trade | SEC |
| 8-K · Current report | Feb 2, 2022 | Material contract | SEC |
| 4 · Change in ownership | Jan 13, 2022 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jan 13, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 23, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Nov 23, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2021 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 15, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 9, 2021 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 19, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2021 | Insider trade | SEC |
| 8-K · Current report | Jul 6, 2021 | Current report | SEC |
| 4 · Change in ownership | Jun 24, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | May 10, 2021 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2021 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2021 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Apr 27, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 22, 2021 | Insider trade | SEC |
| 10-K · Annual report | Mar 16, 2021 | Annual report | SEC |
| 4 · Change in ownership | Feb 1, 2021 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 23, 2020 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 18, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2020 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2020 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Oct 2, 2020 | Offer document | SEC |
| 4 · Change in ownership | Sep 21, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2020 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 10, 2020 | Quarterly report | SEC |
| 8-K · Current report | Jun 29, 2020 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 11, 2020 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2020 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2020 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 25, 2020 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 19, 2020 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 19, 2020 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 19, 2020 | Insider trade | SEC |
| 10-K · Annual report | Mar 16, 2020 | Annual report | SEC |
| 4/A · Change in ownership, amended | Mar 5, 2020 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Feb 19, 2020 | Insider trade | SEC |
| SC TO-I/A | Feb 19, 2020 | Acquisition or disposal | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2020 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2020 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 14, 2020 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 13, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2020 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 13, 2020 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2020 | Big-stake notice | SEC |
| SC TO-I/A | Feb 13, 2020 | Acquisition or disposal | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2020 | Big-stake notice | SEC |
| SC TO-I/A | Feb 13, 2020 | Acquisition or disposal | SEC |
| 3 · Initial statement of ownership | Feb 11, 2020 | Insider trade | SEC |
| SC TO-I/A | Feb 5, 2020 | Acquisition or disposal | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 21, 2020 | Big-stake notice | SEC |
| SC TO-I | Jan 14, 2020 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Jan 9, 2020 | Insider trade | SEC |
| 8-K · Current report | Dec 30, 2019 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Dec 11, 2019 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2019 | Material contract | SEC |
| 4 · Change in ownership | Dec 4, 2019 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2019 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 8, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Nov 8, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2019 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 9, 2019 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 9, 2019 | Quarterly report | SEC |
| 8-K · Current report | Jul 16, 2019 | Management or board change | SEC |
| 4 · Change in ownership | Jul 1, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2019 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2019 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | Jun 12, 2019 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 6, 2019 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2019 | Material contract | SEC |
| 424B5 · Prospectus | Jun 3, 2019 | Offer document | SEC |
| S-3MEF | May 31, 2019 | Other filings | SEC |
| 424B5 · Prospectus | May 30, 2019 | Offer document | SEC |
| 8-K · Current report | May 30, 2019 | Current report | SEC |
| 8-K · Current report | May 30, 2019 | Current report | SEC |
| 10-Q · Quarterly report | May 9, 2019 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2019 | Material contract | SEC |
| 424B5 · Prospectus | May 1, 2019 | Offer document | SEC |
This page holds 200 of 410 filings. Open Filings
Cap table
Built by 6ix from XBiotech Inc.’s releases · as of Nov 12, 2026
- Common shares
- 30,487,731
- Fully diluted
- 30,487,731
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 30,487,731 | Nov 12, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 12, 2026 | 30,487,731 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Daniel Vasella Other companies: American Express Company (Director · Since at least Jul 19, 2012); PepsiCo, Inc. (Director · Since at least Oct 1, 2006) | Director · Apr 14, 2015 – Jun 19, 2017 · Past |
| Benjamin Guzman | Sr.VP Corp. Strategy & Finance · Jul 1, 2017 – Jul 7, 2017 · Past |
| Craig Evan Rademaker | Director · Since at least Aug 29, 2025 |
| David Spencer Soffer | Director · Since at least Aug 29, 2025 |
| Dawn McCollough | VP Clinical Operations · May 16, 2016 – May 19, 2016 · Past |
| Donald H MacAdam | Director · Mar 20, 2018 – Jun 20, 2024 · Past |
| Jan-Paul Waldin | Director · Feb 27, 2018 – Jun 20, 2024 · Past |
| John Simard | Director · Since at least Oct 23, 2026 |
| Kelly Thornburg | SVP of Operations · Jun 8, 2015 – Jun 8, 2015 · Past |
| Mike Cavalier | Vice President of Manufacturing · Since at least Nov 4, 2026 |
All 18 people
| Person | Seat |
|---|---|
| Norma Gonzalez | Vice President of Quality · Since at least Nov 5, 2026 |
| Peter Libby | Director · Jul 10, 2019 – Jun 20, 2024 · Past |
| Qian Wu | Senior Vice President of Clinical Operations and Analytical Quality · Since at least Nov 5, 2026 |
| Queena Han | VP Finance & HR · Apr 14, 2015 – Nov 19, 2021 · Past |
| Sushma Shivaswamy | Chief Scientific Officer, Interim Chief Executive Officer · Since at least Feb 10, 2023 |
| Tevi David Troy | Director · Since at least Aug 29, 2025 |
| Thomas Martin Kuendig | Director · Since at least Aug 29, 2025 |
| W Thorpe McKenzie | Director · Apr 14, 2015 – Jun 20, 2024 · Past |
Log in to ask 6ix AI your own questions about XBiotech Inc.